Physiologic and temporal variation in hepatic elimination of midazolam
- PMID: 7083724
- DOI: 10.1038/clpt.1982.133
Physiologic and temporal variation in hepatic elimination of midazolam
Abstract
Midazolam kinetics were evaluated in six healthy male subjects after single oral (15 mg)and intravenous (0.075 mg/kg) doses. The three-part randomized crossover study consisted of a morning dose in supine position (part A) and morning (part B) and evening (part C) doses under ambulant (sitting/walking) conditions. While no significant changes could be observed in the absorption and distribution process or the elimination half lives, total plasma clearance was higher during part A (616+/-157 ml/min, P=0.01) and C(463+/-82 ml/min, P=0.02), than in part B (317+/-110 ml/min, +/-SD). Since the intrinsic (oral) clearance was also higher during part A (1656+/-657 ml/min, P=0.003) and C(1310+/-579 ml/min, P=0.024) than during part B(710+/-241 ml/min), bioavailability did not change (range 37 to 44%). These data indicate that posture and circadian rhythm are important variables affecting blood flow-dependent hepatic elimination of midazolam.
Similar articles
-
Midazolam kinetics.Clin Pharmacol Ther. 1981 Nov;30(5):653-61. doi: 10.1038/clpt.1981.217. Clin Pharmacol Ther. 1981. PMID: 6117393
-
Effect of age, gender, and obesity on midazolam kinetics.Anesthesiology. 1984 Jul;61(1):27-35. Anesthesiology. 1984. PMID: 6742481
-
Prolonged midazolam elimination half-life.Br J Clin Pharmacol. 1986 Apr;21(4):425-9. doi: 10.1111/j.1365-2125.1986.tb05217.x. Br J Clin Pharmacol. 1986. PMID: 2939863 Free PMC article.
-
High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.Clin Pharmacokinet. 1986 Mar-Apr;11(2):87-106. doi: 10.2165/00003088-198611020-00001. Clin Pharmacokinet. 1986. PMID: 3514045 Review.
-
Dose adjustment in patients with liver disease.Drug Saf. 2005;28(6):529-45. doi: 10.2165/00002018-200528060-00005. Drug Saf. 2005. PMID: 15924505 Review.
Cited by
-
No evidence of a genetic polymorphism in the oxidative metabolism of midazolam.Clin Pharmacokinet. 1988 Nov;15(5):319-25. doi: 10.2165/00003088-198815050-00004. Clin Pharmacokinet. 1988. PMID: 3203485
-
Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state.Br J Clin Pharmacol. 1988 Feb;25(2):243-50. doi: 10.1111/j.1365-2125.1988.tb03297.x. Br J Clin Pharmacol. 1988. PMID: 3358886 Free PMC article. Clinical Trial.
-
Is cyclosporin A an inhibitor of drug metabolism?Br J Clin Pharmacol. 1990 Jul;30(1):71-7. doi: 10.1111/j.1365-2125.1990.tb03745.x. Br J Clin Pharmacol. 1990. PMID: 2390433 Free PMC article.
-
Midazolam. A review of its pharmacological properties and therapeutic use.Drugs. 1984 Dec;28(6):519-43. doi: 10.2165/00003495-198428060-00002. Drugs. 1984. PMID: 6394264 Review.
-
Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites.Br J Clin Pharmacol. 1983;16 Suppl 1(Suppl 1):63S-69S. doi: 10.1111/j.1365-2125.1983.tb02272.x. Br J Clin Pharmacol. 1983. PMID: 6138083 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources